Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 A.R.R.O.W. study

María‐Victoria Mateos; Heinz Ludwig; Shaji Kumar; Cara A. Rosenbaum; Mei Huang; Amanda Goldrick; Julie Blædel; Meletios A Dimopoulos

doi:10.1016/j.clml.2019.09.047

Related publications

Article2019

Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 A.R.R.O.W. Study

María‐Victoria Mateos, Heinz Ludwig, Shaji Kumar, Cara A. Rosenbaum, Mei Huang, Amanda Goldrick, Julie Blædel, Meletios A Dimopoulos

Article2019

Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study.

María‐Victoria Mateos, Heinz Ludwig, Shaji Kumar, Cara A. Rosenbaum, Mei Huang, Amanda Goldrick, Julie Blædel, Meletios A Dimopoulos

Article2019

PS1379 SAFETY AND EFFICACY OF ONCE‐WEEKLY CARFILZOMIB DOSING IN FRAIL PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE 3 A.R.R.O.W. STUDY

M.‐V. Mateos, Heinz Ludwig, Sukashree Suresh Kumar, C. Rosenbaum, Mo Huang, Amanda Goldrick, Julie Blædel, Meletios A Dimopoulos

Article2018

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Philippe Moreau, A. Keith Stewart, Antonio Lazzaro, Meletios A Dimopoulos, Michèle Cavo, Sikander Ailawadhi, Karim Iskander, Mei Huang, Anita Zahlten‐Kumeli, María‐Victoria Mateos

Article2018

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

Philippe Moreau, María‐Victoria Mateos, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten‐Kumeli, A. Keith Stewart

Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 A.R.R.O.W. study

Discussion(0)

Related publications

Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 A.R.R.O.W. Study

Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study.

PS1379 SAFETY AND EFFICACY OF ONCE‐WEEKLY CARFILZOMIB DOSING IN FRAIL PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE 3 A.R.R.O.W. STUDY

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study